LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback
Déjà Vu: 2021 Slump In Psychedelic Stocks Mirrors 2020
Low share prices. VERY low trading volumes. The slump in psychedelic stocks in 2021 looks a lot like the slump in 2020.
Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back
Cybin adds several experts in mental health to its Clinical Advisory Board.
Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP
Digital therapeutics is the wave of the future in healthcare. The psychedelic drug industry is at the forefront for this new tech.
Novamind Increases Strategic Investment in Bionomics
Novamind increases its strategic investment in Bionomics Limited, in support of its plans for a Phase IIb clinical trial for PTSD.
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
A New England Journal of Medicine study found CMPS's COMP360 psilocybin therapy performed better than the leading antidepressant.
MINDCURE (CSE: MCUR | OTC: MCURF) Announces The Addition Of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience In Medical Psychoactive Segment
Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience And Will Help To Drive MINDCURE’s Commercial Focus And Strategic Partnerships
Psychedelic Drugs: The Cure For ‘COVID Isolation Syndrome’?
A recent study shows HALF of all adults already experiencing anxiety due to the social isolation from COVID-19 lockdowns. COVID Isolation Syndrome.
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
Ireland-based GH Research has just raised $125 million in an oversubscribed Series B financing round.
Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening
Mydecine commences screening psilocybin-based drug candidates.
Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications
Cybin prepares two drug candidates, CYB003 and CYB004 for Investigational New Drug applications.
Breaking News: MINDCURE (CSE: MCUR | OTC: MCURF) Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform
Utilizing Speak Ai’s technology, iSTRYM will provide-AI-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy
